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Background: ESPRIT, is a phase III, open-label, randomized, international clinical
trial evaluating the effects of subcutaneous recombinant interleukin-2 (rIL-2) plus
antiretroviral therapy (ART) versus ART alone on HIV-disease progression and death
in HIV-1–infected individuals with CD4+ T-cells ≥300 cells/µL. Objectives: To
describe the baseline characteristics of participants randomized to ESPRIT overall
and by geographic location. Method: Baseline characteristics of randomized
participants were summarized by region. Results: 4,150 patients were enrolled in
ESPRIT from 254 sites in 25 countries. 41%, 27%, 16%, 11%, and 5% were enrolled
in Europe, North America, South America, Asia, and Australia, respectively. The
median age was 40 years, 81% were men, and 76%, 11%, and 9% were Caucasian,
Asian, and African American or African, respectively. 44% of women enrolled (n =
769) were enrolled in Thailand and Argentina. Overall, 55% and 38% of the cohort
acquired HIV through male homosexual and heterosexual contact, respectively.
25% had a prior history of AIDS-defining illness; Pneumocystis jirovecii pneumonia,
M. tuberculosis, and esophageal candida were most commonly reported. Median
nadir and baseline CD4+ T-cell counts were 199 and 458 cells/µL, respectively. 6%
and 13% were hepatitis B or C virus coinfected, respectively. Median duration of
antiretroviral therapy (ART) was 4.2 years; the longest median duration was in
Australia (5.2 years) and the shortest was in Asia (2.3 years). 17%, 13%, and 69% of
participants began ART before 1995, between 1996 and 1997, and from 1998
onward, respectively. 86% used ART from two or more ART classes, with 49% using
a protease inhibitor–based regimen and 46% using a nonnucleoside reverse
transcriptase inhibitor–based regimen. 78% had plasma HIV RNA below detection
(<500 cp/mL). Conclusion: ESPRIT has enrolled a diverse population of HIV-
infected individuals including large populations of women and patients of African-
American/African and Asian ethnicity often underrepresented in HIV research. As a
consequence, the results of the study may have wide global applicability. Key
words: AIDS-defining illnesses, ESPRIT, HIV, progression of disease, recombinant
interleukin-2ESPRIT • PETT ET AL. 71
D
espite the enormous benefits of combination
antiretroviral therapy (ART) in HIV-infec-
tion, there are a number of limitations to its
Antiretroviral Therapy),
21 comparing the clinical
impact, with respect to AIDS-defining illnesses
(ADI) and death in HIV-1–infected patients, of in-
termittent dosing cycles of SC rIL-2 with ART ver-
sus ART alone over at least 5 years of follow-up. In
order to understand the impact of rIL-2 in a broad
population of people with HIV, the ESPRIT trial
recruited from a diverse population of patients
around the world who had access to combination
ART – including intermittent (i.e., a noncontinuous
supply) access – and who were being cared for in a
variety of clinical practice settings. To be as inclu-
sive as possible, there were relatively few inclusion
and exclusion criteria; exclusions included patients
in whom receipt of rIL-2 might represent a poten-
tial safety issue (i.e., concurrent malignancy requir-
ing cytotoxic chemotherapy); use of systemic corti-
costeroids, immunosuppressants, or cytotoxic
agents within 45 days prior to study randomiza-
tion; any CNS abnormality that required ongoing
treatment with antiseizure medication; current or
historical autoimmune/inflammatory diseases;
pregnancy; or breastfeeding. The present article
describes the baseline characteristics overall and
for selected subgroups of participants in ESPRIT.
MATERIALS AND METHOD
Study Population
Prior to the initiation of ESPRIT, four ESPRIT
phase II Vanguard studies were conducted. In all,
729 patients were enrolled; of these, 638 were en-
rolled into ESPRIT as described in the article by
Tavel and colleagues.
22 In ESPRIT, eligible patients
were HIV-infected adults (≥18 years) with CD4+ T-
cell count of ≥300 cells/µL (within 45 days of ran-
domization) and on or starting combination ART.
In the Vanguard studies and version 1.0 of the
protocol, patients had Centers for Disease Control
and Prevention (CDC) category A/B HIV disease
at enrollment; version 2.0 of the protocol allowed
the enrollment of CDC category C patients provid-
ing they had no active ADI for 12 months.
The trial is being conducted in accordance with
the International Conference on Harmonisation of
Technical Requirements for Registration of Phar-
maceuticals for Human Use–Good Clinical Practice
(ICH-GCP) guidelines. ESPRIT has been approved
by the institutional review board for each partici-
pating site and is sponsored by the National Insti-
efficacy and durability including the failure to
eradicate virus.
1,2 Moreover, incomplete viral sup-
pression, in some cases due to poor adherence but
also due to different potency of ART regimens and
different pharmacokinetic profiles, can lead to loss
of viral control and development of drug-resistant
viral strains.
3 In addition, ART is associated with
cumulative toxicities, including significant meta-
bolic disturbances, which impact on body habitus
and have the potential to accelerate atherosclero-
sis.
4,5 Furthermore, many toxicities may be exacer-
bated by coinfection with hepatitis B virus (HBV)
and hepatitis C virus (HCV).
6
Current ART guidelines
7 echo uncertainty re-
garding initiation and duration of ART and con-
trast markedly with previous statements recom-
mending early institution of therapy aimed at
suppression of plasma virus to undetectable levels.
This is in large part due to the recognition that
there are long-term toxicities associated with ART
and, as a consequence, alternative approaches for
clinical management are needed. A number of
phase I/II randomized studies of subcutaneous re-
combinant interleukin-2 (SC rIL-2) have estab-
lished that intermittent dosing cycles of rIL-2 in
combination with ART increase CD4+ T-cell counts
significantly more than ART alone.
8–15 Naïve CD4+
T cells are preferentially expanded, including a
unique subset of CD4+ CD25+ naïve T cells, and
may remain elevated for many years without fur-
ther rIL-2 dosing.
16,17 Kovacs et al.
18 have recently
described two mechanisms that contribute to this:
increased proliferation of CD4+ T cells and to a
lesser extent CD8+ T cells during rIL-2 dosing
coupled with prolonged survival of these naïve
CD4+ T cells and the central memory pool of CD4+
T cells. None of the earlier studies of rIL-2 therapy
in HIV infection has been powered to show that the
rIL-2–induced CD4+ T cell increases are associated
with additional clinical benefit compared to the use
of ART alone, although the pooled analysis
19 im-
plied a clinical benefit of rIL-2. To this end, there
are two ongoing, fully enrolled, phase III, open-
label, randomized studies, ESPRIT (Evaluation of
Subcutaneous Proleukin
® in a Randomized Inter-
national Trial)
20 and SILCAAT (Subcutaneous Re-
combinant, Human Interleukin-2 in HIV-Infected
Patients with Low CD4+ Counts Under Active72 HIV CLINICAL TRIALS • 7/2 • MAR-APR 2006
tute of Allergy and Infectious Diseases (NIAID) of
the National Institutes of Health (NIH). Informed
consent has been obtained from all patients.
Trial Design
ESPRIT is a randomized, open-label, clinical end-
point study of intermittent SC rIL-2 plus ART versus
ART alone. Patients were randomized on a 1:1 basis
to receive intermittent open-label SC rIL-2 with ART
or ART alone. The primary endpoint is HIV progres-
sion of disease or death. The definition of the former
includes all conditions classified in the CDC cat-
egory C 1993 revised classification
23 plus 12 other
conditions that have been associated with HIV-re-
lated immunodeficiency.
24 Details of the study de-
sign including the sample size justification and sta-
tistical methodology have been published.
20
SC rIL-2 Treatment
In ESPRIT, the induction phase consists of SC
rIL-2 at a starting dose of 7.5 MIU given twice daily
for 5 consecutive days every 8 weeks for three dos-
ing cycles. Following induction, patients are given
further rIL-2 dosing cycles to achieve or sustain the
CD4+ T-cell “goal.” The latter is based upon entry
CD4+ T-cell count, that is, a doubling of baseline
CD4+ T-cell count if entry CD4+ was between 300–
499 cells/µL or CD4+ ≥1000 cells/µL if entry CD4+
T-cell count was ≥500 cells/mL. All patients are
seen every 4 months for the duration of the study.
Statistical Analyses
Summary statistics – frequency distributions,
means, medians, and interquartile range (IQR) – are
used for describing the cohort overall and by geo-
graphic region, age, gender, coinfection with hepati-
tis B and C, and duration and type of ART. Analyses
were performed using Statistical Analyses Software
(SAS) Version 8.2 (SAS Institute, Cary, North Caro-
lina, USA) and STATA Release 8.0 (STATA Corpo-
ration, College Station, Texas, USA) software.
RESULTS
Overall Baseline Characteristics
ESPRIT was fully enrolled with 4,150 patients in
May 2003. These patients were accrued from 254
sites in 25 different countries across six continents
(Table 1). The majority of clinical sites were in
Europe (including one site in Morocco; n = 103) and
North America (n = 99). The percentages of pa-
tients enrolled by sites in Europe, North America,
South America, Asia, Australia, and Africa were
41%, 27%, 16%, 11%, 5%, and 0.6%, respectively.
The median age was 40 years, and 19% of patients
were women (Table 2). Overall, 76%, 11%, and 9%
Table 1. Number of sites and patients enrolled in ESPRIT by geographic region
Europea Asiab North Americac South Americad Australiae
(n; % of total (n; % of total (n; % of total (n; % of total (n; % of total Total
enrollment) enrollment) enrollment) enrollment) enrollment) (n)
Sites 103 12 99 16 24 254
Patients 1,690 (41%) 474 (11%) 1,129 (27%) 652 (16%) 205 (5%) 4,150
enrolled
aEurope as described by participant countries (no. of sites, no. of patients enrolled): Austria (2 sites, n = 3); Belgium (1 site, n = 80);
Denmark (5 sites, n = 72); France (22 sites, n = 182); Germany (10 sites, n = 266); Ireland (1 site, n = 4); Italy (8 sites, n = 104);
Netherlands (6 sites, n = 54); Norway (1 site, n = 8); Poland (4 sites, n = 100); Portugal (3 sites, n = 107); Spain (16 sites, n = 308);
Sweden (2 sites, n = 7); Switzerland (1 site, n = 10); United Kingdom (20 sites, n = 328); Morocco (1 site, n = 26).
bAsia as described by participant countries (no. of sites, no. of patients enrolled): Israel (3 sites, n = 64); Japan (3 sites, n = 25);
Thailand (5 sites, n = 365; Singapore (1 site, n = 20).
cNorth America as described by participant countries (no. of sites, no. of patients enrolled): USA (85 sites, n = 988); Canada (14
sites, n = 141).
dSouth America as described by participant countries (no. of sites, no. of patients enrolled): Argentina (13 sites, n = 554); Brazil (3
sites, n = 98).
eAustralia as described by no. of sites, no. of patients enrolled (24 sites, n = 205).ESPRIT • PETT ET AL. 73
Table 2.
Baseline characteristics of the ESPRIT cohort grouped by geographic region
Europe,
including
Characteristic
Morocco
Asia
North America
South America
Australia
Total
Age, yrs [median (IQR)]
41 (36–48)
35 (31–40)
42 (36–48)
37 (33–44)
43 (37–49)
40 (35–47)
Female [
n
 (% of region’s total)]
252 (15%)
228 (48%)
117 (10%)
164 (25%)
8 (4%)
769 (19%)
Male, age <35 yrs [
n
 (% of region’s total)]
236 (33%)
87 (12%)
198 (28%)
165 (23%)
34 (5%)
720
Male, age 35–44 yrs [
n
 (% of region’s
665 (44%)
122 (8%)
441 (29%)
208 (14%)
81 (5%)
1,517
total)]
Male, age >45 yrs [
n
 (% of region’s total)]
537 (47%)
37 (3%)
373 (33%)
115 (10%)
82 (7%)
1,144
Female, age <35 yrs [
n
 (% of region’s
74 (22%)
142 (41%)
39 (11%)
84 (25%)
4
 (1%)
343
total)]
Female, age 35–44 yrs [
n
 (% of region’s
135 (44%)
71 (23%)
50 (16%)
52 (17%)
2
 (1%)
310
 total)]
Female, age >45 yrs [
n
 (% of region’s
43 (37%)
15 (13%)
28 (24%)
28 (24%)
2
 (1%)
116
total)]
All, age <35 yrs [
n
 (% of region’s total)]
310 (18%)
229 (48%)
237 (21%)
249 (38%)
38 (19%)
1
,063
All, age 35–44 yrs [
n
 (% of region’s total)]
800 (47%)
193 (41%)
491 (43%)
260 (40%)
83 (40%)
1
,827
All, age >45yrs [
n
 (% of region’s total)]
580 (34%)
52 (11%)
401 (36%)
143 (22%)
84 (41%)
1
,260
White [
n
 (% of region’s total)]
1,559 
(92%)
41 (9%)
727 (64%)
585 (90%)
186 (90%)
3,098 
(76%)
Acquisition of HIV via IVDU [
n
 (% of
229 (14%)
18 (4%)
97 (9%)
83 (13%)
5
 (2%)
432 (10%)
region’s enrollment)]
Baseline CD4+ T-cell count, cells/µL
442 (365–563)
422 (361–510)
513 (410–664)
447 (361–574)
450 (370–572)
458 (373–588)
[median (IQR)]
Baseline CD4+, % [median (IQR)]
23 (19–29)
21 (17–27)
27 (21–33)
24 (19–30)
23 (18–28)
24 (19–30)
Nadir CD4+ T-cell count, cells/µL
153 (62–244)
265 (158–352)
265 (147–374)
200 (100–314)
176 (84–256)
199 (92–310)
 [median (IQR)]
Median difference (baseline – nadir)
304 (213–396)
192 (62–305)
268 (148–396)
260 (165–368)
287 (206–380)
277 (172–382)
CD4+ T-cell count, cells/µL
Prior AIDS events
565 (33%)
58 (12%)
171 (15%)
182 (28%)
61 (30%)
1,037 
(25%)
HIV RNA <400 cp/mL
1,327 
(79%)
260 (55%)
767 (68%)
352 (54%)
127 (62%)
2
,833
HBV sAg +ve
97 (6%)
36 (8%)
59 (5%)
24 (4%)
12 (6%)
228 (5.5%)
HCV +ve
283 (17%)
34 (7%)
113 (10%)
84 (13%)
9 (4%)
523 (13%)
Duration of ART, yrs [median (IQR)]
4.8 (2.7–7.0)
2
.3 (0.5–4.2)
4
.0 (2.1–6.7)
3
.6 (1.9–5.3)
5
.2 (3.9–8.8)
4.2 (2–6)
BMI, kg/m
2
 [median (IQR)]
23.2 (21.6–25.3)
21.8 (20.1–24.0)
25.1 (23.2–27.6)
24.1 (22.4–25.7)
23.5 (21.8–25.8)
24.0 (22.0–26.0)
Note: 
ART = antiretroviral therapy; BMI = body mass index; IVDU = intravenous drug use; IQR = interquartile range; HBV sAg +ve = hepa titis B virus surface antigen positive; HCV +ve
= hepatitis C virus positive.74 HIV CLINICAL TRIALS • 7/2 • MAR-APR 2006
were of Caucasian, Asian, and African-American/
African ethnicity. HIV was acquired through male
homosexual sex in 55% of men and was hetero-
sexually acquired in 38% of patients; 10% of pa-
tients reported intravenous drug use (IVDU) alone
as a mode of HIV transmission. In the mixed cat-
egories where more than one risk factor for disease
acquisition was reported, male homosexual/IVDU
and heterosexual/IVDU risks were reported in 1%
and 3%, respectively. Blood products were re-
ported as the sole means of HIV transmission in 50
patients (1% of the total).
The median duration of HIV infection was 6
years (median IQR 3–10 years). Median nadir and
baseline CD4+ T cells were 199 cells/µL and 458
cells/µL (24%), respectively; median difference in
CD4+ T cells (baseline minus nadir) was 277 cells/
mL. Twenty-five percent of patients had a history
of prior ADI. The most common prior ADIs re-
corded, in descending order of frequency, were
Pneumocystis carinii (jirovecii) pneumonia (PCP), M.
tuberculosis, esophageal candida, Kaposi’s sarcoma,
cytomegalovirus (CMV) infection, cerebral toxo-
plasmosis, disseminated Herpes zoster, and HIV-
wasting syndrome. Non-category C ADI made up
12% of all ADIs reported at baseline. In comparing
those participants with prior ADI to those without,
the median age was older at 42 years versus 39
years (p ≤ .0001), CD4+ T-cell nadir was signifi-
cantly lower at 62 versus 239 cells/µL (p ≤ .0001),
and baseline CD4+ T cells were also lower at 418
versus 472 cells/µL (p ≤ .0001), respectively. The
median duration of ART use was 4.2 years (median
IQR 2–6 years) (Table 2); 17%, 13%, and 69% of
patients commenced ART in the pre-highly active
antiretroviral therapy (pre-HAART; 1994–1995),
early HAART (1996–1997), and late HAART
(1998+) eras, respectively. Seventy-eight percent,
16%, and 5% had a viral load below the level of
quantification (<500 copies/mL), between 500–
9,999 copies/mL, or ≥10,000 copies/mL, respec-
tively. The majority of patients (50%) were taking a
three-drug combination, with 14%, 2%, and 0.4%
on 4, 5, and ≥6 drug combinations, respectively.
Fourteen percent, 77%, and 9% of patients were on
drugs from one, two, and three classes of ART,
respectively. Forty-six percent were on ART con-
taining nonnucleoside reverse transcriptase inhibi-
tors (NNRTIs) and 49% were on a protease inhibi-
tor (PI)–based regimen; 15% were using
ritonavir-boosted PI (Table 3). Overall, 18% were
reported as having peripheral lipodystrophy (thin-
ning of the face, limbs, or upper trunk) and 9% as
having accumulation of fat in the abdomen, neck,
or breasts. Ten percent had dyslipidaemia that was
being treated with lipid-lowering medication; 2%
had diabetes mellitus that was being treated with
oral hypoglycaemic agents or insulin, and 5% had
hypertension that required drug treatment. Less
than 1% of patients gave a history of prior myocar-
dial infarction or stroke. The most common pro-
phylaxes used were against PCP and Herpes sim-
plex in 6% and 5% of the cohort, respectively.
At baseline, 14% (n = 585), 37% (n = 1,536), and
36% (n = 1,494) of the patients did not have results
for hepatitis B virus surface antigen (HBV sAg),
hepatitis B virus surface antibody (HBV sAb), and
hepatitis B virus core antibody (HBV cAb) status,
respectively. Of those for whom these data were
available, 6% were HBV sAg positive and 31%
were HBV cAb positive. Thirteen percent were
HCV coinfected, and 28 (0.8%) had dual infection
with HBV and HCV (defined as hepatitis C anti-
body and HBV sAg positive). Overall, 17% (n =
680) had received a full course of hepatitis B vacci-
nations and 83% (n = 3,410) had not. There was no
difference in the HBV sAb status in those reporting
a full course of hepatitis B vaccination compared to
those who were not vaccinated or were non-
completers (36% vs. 31%, respectively). Six percent
of those with HCV coinfection had received vacci-
nation against HBV; however, 51% (n = 265) of
patients with HCV coinfection were also HBV cAb
positive, indicating past exposure and immunity to
HBV. Median weight of the cohort was 72 kg (IQR
65–93 kg) equivalent to a median body mass index
(BMI) of 24 kg/m
2 (IQR 22–26 kg/m
2).
Baseline Characteristics by Geographic Region
The baseline characteristics of the ESPRIT pa-
tients according to their geographic region of en-
rollment are described in Table 2. Key differences
were that patients enrolled in Asia and Argentina
were younger and 48% of patients enrolled in Asia
and 25% in South America were female. Moreover,
44% (n = 336) of all women enrolled (n = 769) were
enrolled in Thailand and Argentina, equating to
54% and 25% of each of these country’s total enroll-
ment into ESPRIT, respectively. Eighty-one percent
of patients enrolled in Asia were infected through
heterosexual sex compared to much lower rates inESPRIT • PETT ET AL. 75
Table 3.
Baseline characteristics by duration of ART
ART duration 
≤
2
ART duration 2–4
ART duration 4–6
ART duration >6
 yrs (
n
 = 928)
 yrs (
n
 = 1,030)
 yrs (
n
 = 999)
 yrs (
n
 = 1,138)
Total
a
No. of ART drugs in use at baseline
None
2 (0.2%)
1 (0.1%)
—
2
 (0.2%)
5
1
37 (4%)
36 (4%)
33 (3%)
25 (2%)
131
2
462 (50%)
335 (33%)
280 (28%)
184 (16%)
1
,261
3+
424 (46%)
653 (63%)
668 (67%)
869 (76%)
2
,614
5+
3 (0.3%)
6 (0.6%)
18 (1.8%)
58 (5%)
85
Classes of ART drugs in use at baseline
None
2 (0.2%)
1 (0.1%)
—
2
 (0.2%)
5
1
206 (22%)
120 (12%)
147 (15%)
89 (8%)
562
2
697 (75%)
875 (85%)
771 (77%)
825 (73%)
3
,168
3
23 (2%)
34 (3%)
80 (8%)
217 (19%)
354
4
—
(3%)
1
 (0.1%)
5 (0.4%)
6
Use of NNRTI
437 (47%)
467 (45%)
413 (41%)
575 (51%)
1
,892
Use of PI
306 (33%)
473 (46%)
527 (53%)
701 (62%)
2
,007
Use of ritonavir-boosted PI
58 (6%)
99 (10%)
167 (17%)
294 (26%)
618
Peripheral fat loss +/- fat accumulation
25 (3%)
161 (16%)
257 (26%)
398 (35%)
841
Dyslipdaemia treated with lipid-lowering
agents
24 (3%)
90 (9%)
119 (12%)
247 (22%)
480
Hypertension treated with
anti-hypertensives
21 (2%)
49 (5%)
50 (5%)
92 (8%)
212
HIV RNA <400 cp/mL
582 (63%)
772 (75%)
671 (67%)
776 (68%)
2
,801
Baseline CD4+ T-cell count, cells/µL
[median (IQR)]
449 (374–577)
478 (380–607)
464 (367–588)
446 (370–562)
Nadir CD4+ T-cell count, cells/µL
 [median (IQR)]
274 (176–377)
196 (90–310)
185 (80–280)
149 (65–248)
Median difference (baseline – nadir)
CD4+ T-cell count, cells/µL
200 (98–298)
297 (188–398)
290 (199–392)
306 (210–411)
CD4+ T-cell slope in the 12 months
prior to study entry
118 (-50, 284)
51 (-106, 200)
-0.24 (-158, 161)
37 (-122,175)
Note:  
ART = antiretroviral therapy; NNRTI = nonnucleoside reverse transcriptase inhibitor; PI = protease inhibitor.
 
a
Data missing on 55 people and 5 people were not on any ART at baseline.76 HIV CLINICAL TRIALS • 7/2 • MAR-APR 2006
the other regions: 28%, 36%, 49%, and 6% in Eu-
rope, North America, South America, and Austra-
lia, respectively. IVDU as the route of HIV acquisi-
tion was most commonly reported in Europe (14%)
and South America (13%). In countries with more
than 20 patients enrolled, the highest rates of HIV
acquisition via IVDU were in Poland (56%), Spain
(32%), Italy (30%), Israel (16%), and Argentina
(14%), with much lower rates in the other northern
European countries (≤3%), Australia (2%), Canada
(6%), Brazil (5%), and Thailand (2%).
In those countries with at least 20 patients en-
rolled, the longest duration of HIV-infection (i.e.,
the time since their first positive HIV test) was in
patients enrolled in France (9.5 years), Australia (9
years), and Belgium (8.4 years). The time since first
HIV diagnosis was shortest in Asia (3 years; me-
dian IQR 2–6 years), which is mostly due to the
large number of patients enrolled in Thailand (77%
of total enrollment from Asia) where the median
duration was 3 years. Thirty-three and 30% of pa-
tients enrolled in Europe and Australia, respec-
tively, had a prior ADI. In contrast, 15% of those in
North America and 12% of those in Asia had a
prior ADI. PCP was the most common prior ADI in
all continents. Prior PCP was most common in Eu-
rope (n = 201; 12%), South America (n = 75; 11%),
and Australia (n = 22; 11%). M. tuberculosis was the
second most commonly recorded previous ADI;
the highest percentages were recorded in patients
enrolled in South America (n = 39; 6%), Europe (n =
95; 6%), and Asia (n = 25; 5%). In Europe, 30% of
patients with prior tuberculosis were enrolled in
Spain (n = 28). Forty-eight percent of the 1,037 par-
ticipants who reported prior ADI were enrolled
from four countries: United Kingdom (n = 144),
Argentina (n = 142), Spain (n = 118), and Germany
(n = 90).
Baseline CD4+ T-cell count and percentage at
enrollment were highest in North America (513
cells/µL and 27%, respectively). Nadir CD4+ T
cells were lowest in Europe (153 cells/mL) and
Australia (176 cells/mL). The median difference
between nadir and baseline CD4+ T cells was low-
est in Asia (192 cells/µL). The median duration of
ART use was shortest in Asia (median 2.3 years)
and South America (median 3.6 years). In countries
enrolling more than 20 patients, use of NNRTI-
based regimens at study entry was highest in Spain
(n = 308; 66%) and lowest in Denmark (n = 17; 24%).
Ritonavir-boosted PI use at study entry was high-
est in some Northern European countries (Den-
mark [29% of 72 enrolled], Germany [27% of 266
enrolled], Belgium [26% of 80 enrolled], and Aus-
tria [23% of 34 enrolled]), Australia (27% of 205
enrolled), and some sites in North America. The
lowest use of ritonavir-boosted PI at study entry
was in Morocco (0% of 26 enrolled), Netherlands
(7% of 54 enrolled), and Thailand (7% of 365 en-
rolled); however, 66 (18%) patients in Thailand
were enrolled between 1997 and 1998 prior to the
widespread use of either ritonavir-boosted PI or
NNRTI.
Europe and Argentina had the highest rates of
HCV coinfection, mirroring the highest IVDU rates
(Table 2). HBV coinfection rates were highest in
Asia (8%) and Europe (6%). Use of prophylaxis
against Herpes infections was highest in the United
States, Australia, and the United Kingdom and was
lowest (≤1%) in Argentina, Brazil, and Thailand.
All patients had BMI in the normal range (18.5–24.9
kg/m
2), aside from those in North America where
median BMI was just in the “overweight” range
(Table 2). BMI was lowest in Asia (21.8 kg/m
2),
which was in part due to the large number of
women (44% of participants), many of whom were
enrolled in Thailand.
Baseline Characteristics by Gender and Age
The baseline characteristics by age and gender in
the different regions are shown in Tables 2 and 4.
Twenty-six percent of the women versus 7% of the
men enrolled were Asian; 53% of the women and
80% of the men were Caucasian. The women en-
rolled were younger than the men (median age 36
vs. 41 years); 15% and 34% of the women and men
enrolled, respectively, were more than 45 years old.
Women had been diagnosed more recently than
the men (median 5 years; IQR 3–9 years). Nadir
CD4+ T cells were significantly higher in women
than men (232 vs. 190 cells/µL; p ≤ .0001), although
baseline CD4+ T cells at study entry were similar.
Twenty-seven percent of men versus 18% of
women (p < .0001) had a prior ADI at baseline. In
men, the highest rates of prior ADI occurred in
those between the ages of 35–44 years and over 45
years; these two age groups also had the lowest
nadir CD4+ T-cell counts and the longest duration
of ART use. The median duration of ART use was
3.9 years in women and 4.3 years in men. Forty
percent and 39% of women were on an NNRTI or
PI at baseline compared to 47% and 51% of men,
respectively, a significant difference for both pa-ESPRIT • PETT ET AL. 77
Table 4.
Baseline characteristics of the ESPRIT by age group and gender
Male
Male
Male
Female
Female
Female
A
ll
All
(<35 yrs)
(35–44 yrs)
(>45yrs)
(<35 yrs)
(35–44 yrs)
(age >45 yrs)
(<35 yrs)
(35–44 yrs)
All (>45 yrs)
White [
n
 (% of total in
513 (71%)
1202 (79%)
973 (85%)
151 (44%)
184 (59%)
75 (65%)
664 (62%)
1,386 (76%)
1,048 (83%)
each age group)]
Acquisition of HIV via
84 (12%)
201 (13%)
57 (5%)
31 (9%)
49 (16%)
10 (9%)
115 (11%)
250 (14%)
67 (5%)
IVDU [
n 
(% of total in
each age group)]
Baseline CD4+ T-cell
474
460
446
469
436
455
470
456
448
count, cells/µL [median
(380–607)
(372–591)
(369–573)
(382–594)
(367–566)
(376–567)
(380–599)
(371–584)
(370–572)
(IQR)]
Baseline CD4% [median
25 (20–32)
23 (19–29)
22 (18–28)
26 (21–34)
25 (20–31)
24 (19–31)
26 (20–33)
24 (19–30)
23 (18–29)
(IQR)]
Nadir CD4+ T-cell
253
174
175
260
204
210
256
180
179 (85–274)
count, cells/µL
(
147–350)
(72–288)
(85–270)
(153–371)
(100–313)
(97–305)
(149–356)
(77-292)
[median (IQR)]
Median difference
247
293
290
245
254
257
244
289
289
(baseline – nadir)
(129–354)
(191–397)
(191–383)
(105–363)
(145–367)
(151–388)
(121–356)
(182–392)
(189–384)
CD4+ T-cell count,
cells/µL
Prior AIDS events
98 (14%)
439 (29%)
361 (32%)
41 (12%)
71 (23%)
27 (23%)
139 (13%)
510 (28%)
388 (31%)
HIV RNA <400 cp/mL
478 (66%)
1073 (71%)
829 (72%)
164 (48%)
210 (68%)
79 (68%)
642 (60%)
1283 (70%)
908 (72%)
HBV sAg +ve
— (—)
108 (7%)
63 (5%)
— (—)
13 (4%)
4 (3%)
— (—)
121 (7%)
67 (5%)
HCV +ve
a
 [
n
 (% of total
97 (14%)
222 (15%)
87 (8%)
37 (11%)
68 (22%)
12 (11%)
134 (13%)
290 (16%)
99 (8%)
 in each group)]
Duration of ART, yrs
2.7
4
.5
5.0
2
.3
4.3
3
.9
2.5
4
.5
4.9 (2.9–7.8)
[median (IQR)]
(1.3–4.6)
(2.6–6.5)
(3.0–7.9)
(1.2–4.4)
(2.2–6.5)
(2.2–6.2)
(1.3–4.5)
(2.5–6.5)
BMI, kg/m
2
 [median
23.6
24.0
24.4
21.9
22.7
23.9
23.1
23.8
24.4
 (IQR)]
(
21.8–25.6)
(22.1–25.9)
(22.6–24.5)
(20.2–24.0)
(20.6–25.7)
(22.0–27.3)
(21.1–25.2)
(21.8–25.9)
(22.5–26.5
)
Note: 
 IDVU = intravenous drug use; HBV sAg +ve = hepatitis B virus surface antigen positive; ART = antiretroviral therapy; BMI = bod
y mass index.
a
Data missing on 49 patients.78 HIV CLINICAL TRIALS • 7/2 • MAR-APR 2006
rameters. Fewer women than men had
dyslipidaemia being treated with lipid-lowering
drugs (4% vs. 12%). In women, peripheral lipodys-
trophy and accumulation of fat in the abdomen,
neck, or breasts was reported in 15% and 11%,
respectively, which was significantly less than in
men for both parameters.
Baseline Characteristics by Duration of ART
These are summarized in Table 3 and have been
discussed in the overall results. Patients treated
with ART for the longest duration (i.e., over 6
years) were more likely to be taking drugs from
four or more classes of antiretrovirals compared to
patients on treatment for 4 years or less at study
entry. Rates of virological suppression (<400 cp/
mL) were lowest in those on ART for ≤2 years
(63%) and highest (75%) in those on ART for 2–4
years. PI use, including ritonavir-boosted PI, at
study entry was highest in the heavily treated
group (>6 years of ART) and lowest in those
treated for ≤2 years; the latter group had a higher
use of NNRTI (47%) compared to PI use (33%) and
greater use of single class ART (22%) compared to
patients on ART for more than 2 years. The nadir
CD4+ T-cell count of patients treated for <2 years
was significantly higher (median 274 cells/µL)
than that of patients treated for  6 years (median
149 cells/µL). Fat accumulation/loss and
dyslipdaemia requiring treatment with lipid-low-
ering agents correlated with duration of ART expo-
sure, with the highest rates in those with ART of  ≥6
years’ duration.
Baseline Characteristics by HBV or HCV
Infection
These are summarized in Table 5. All those with
HBV and/or HCV coinfection were over 35 years
of age. Twenty-two percent and 11% of those with
HCV or HBV coinfection, respectively, were
women. Hepatitis C coinfection mirrored IVDU as
a mode of HIV acquisition in 61% of patients; in
contrast, HBV coinfection was not closely corre-
lated with IVDU (11%).
DISCUSSION
ESPRIT is the largest trial of an experimental
agent in HIV infection to date. Patients were en-
rolled from 254 sites in 25 countries on six conti-
nents. This wide global coverage, coupled with a
protocol designed to be as inclusive as possible, has
led to the enrollment of a diverse population of
HIV-infected patients across a wide variety of clini-
cal settings. It is hoped that as a consequence the
results will have greater global applicability. Many
prior trials have been criticized for excluding cer-
tain HIV-infected populations, such as the non-
trialing of new agents in women of child-bearing
potential; patients with hepatitis B or C coinfection
with or without ongoing IVDU, and patients from
Asian, African American, and other ethnicities tra-
ditionally underrepresented in clinical research.
25
In light of these criticisms and especially because
there may be gender- and ethnicity-related differ-
ences related to therapeutic response and toxicity
of HIV treatments, the Food and Drug Administra-
tion (FDA) is now permitted to place a hold on the
licensing of investigational agents if, for example,
there are insufficient efficacy and safety data in
women.
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ESPRIT, compared to many other large interven-
tion studies involving antiretroviral therapy, dif-
fers in terms of the sheer magnitude of the study
population (n = 4,150), larger numbers of female
patients, and enrollment of relatively large num-
bers of patients of non-white ethnicity and with
hepatitis C coinfection. Exclusions were minimal
and were predominantly for safety reasons. More-
over, while the ESPRIT entry criteria excluded
women who were pregnant or breastfeeding at the
time of enrollment for safety reasons, the protocol
allows pregnancy on study provided no SC rIL-2
was administered until the pregnancy was over.
The baseline demographics are very similar to
some of the other large observational studies, such
as the ART collaboration cohort
27 and EuroSIDA,
28
in the countries where these cohort studies are be-
ing conducted; the implication is that the ESPRIT
patients are representative of the general popula-
tion of HIV-infected patients in these countries.
We hypothesize that duration of known HIV in-
fection (i.e., time from first positive test), prior ADI,
and access to ART may have influenced patient
selection for ESPRIT participation in different set-
tings. For example, in Australia, patients had been
diagnosed with HIV longer, had lower nadir CD4+
T-cell counts, had high rates of prior ADI, and had
longer duration of ART. In contrast, patients in
Thailand had been diagnosed with HIV infectionESPRIT • PETT ET AL. 79
more recently, had lower rates of prior ADI, had
higher nadir CD4+ T-cell counts, and had shorter
duration of ART. Therefore, patients enrolled in
ESPRIT in Australia were more likely to have been
treated before combination ART was widely used
(i.e., with monotherapy); although these patients
were virologically suppressed at ESPRIT baseline,
they might be expected to have fewer treatment
options (at least at the time of ESPRIT enrollment)
if virological failure were to occur. In contrast, pa-
tients enrolled in Thailand would have access to
one or two combination antiretroviral regimens
with more limited access to future regimens in the
event of virological failure. In both cases, rIL-2
might have been viewed as a way of maintaining a
higher CD4+ T-cell count so that when or if viro-
logical rebound occurred in the absence of an
antiretroviral regimen that could achieve durable
Table 5. Baseline characteristics by coinfection with HBV and HCV
a
HBV and/or
Characteristic HBV sAg +ve HBV sAg -ve HCV +ve HCV -ve HCV -ve
No. (% of total enrollment) 228 (6%) 3,337 (80%) 523 (13%) 2,925 (70%) 3,673 (89%)
Age, yrs [median (IQR)] 41 (37–46) 40 (35–47) 39 (35–44) 41 (35–47) 40 (35–47)
Femaleb 26 (11%) 621 (19%) 117 (22%) 503 (17%) 657 (18%)
Caucasian [n (% of total)] 158 (69%) 2,542 (76%) 438 (84%) 2,199 (75%) 2,797 (76%)
Afro-American/African 32 (14%) 315 (9%) 41 (8%) 302 (10%) 358 (10%)
Asian 33 (14%) 332 (10%) 25 (5%) 302 (10%) 359 (10%)
Acquisition of HIV via IVDU 24 (11%) 353 (11%) 321 (61%) 65 (2%) 365 (105)
[n (% of total)]
Baseline CD4+ T-cell count, 425 (357–551) 460 (373–590) 450 (370–554) 460 (372–594) 459 (371–589)
cells/µL [median (IQR)]
Nadir CD4+ T-cell count, 196 (81–296) 193 (90–298) 178 (81–284) 199 (90–301) 195 (90–300)
cells/µL [median (IQR)]
Median difference (baseline 258 (145–364) 285 (180–388) 284 (177–371) 280 (177–388) 281 (178–385)
– nadir) CD4+ T-cell count,
cells/µL
Prior AIDS events 65 (29%) 837 (25%) 126 (24%) 744 (25%) 930 (25%)
HIV RNA <400 cp/mL 163 (71%) 2,356 (71%) 363 (69%) 2,077 (71%) 2,583 (70%)
Duration of ART, yrs 4.6 (2.3–7.4) 4.1 (2.2–6.3) 4.7 (2.5–7.0) 4.1 (2.1–6.3) 4.2 (2.2–6.4)
[median (IQR)]
BMI, kg/m2 [median (IQR)] 24 (22–26) 23 (22–25) 24 (22–26) 24 (22–26) 24 (22–26)
Note:  HBV sAg +ve = hepatitis B virus surface antigen positive; HBV sAg -ve = hepatitis B virus surface antigen negative; HCV =
hepatitis C virus; IQR = interquartile range; IVDU = intravenous drug use; ART = antiretroviral therapy; BMI = body mass index.
aData on HBV sAg status and HCV status missing in 585 and 702 patients, respectively.
bData on hepatitis B status missing in 14 female patients.80 HIV CLINICAL TRIALS • 7/2 • MAR-APR 2006
viral suppression, patients would potentially re-
main well for longer as a consequence of having
higher CD4+ T-cell counts.
The use of single class ART at study entry mir-
rored by lack of use of PI and NNRTI-based regi-
mens was more common in women than in men.
Limited access to ART in countries in which large
numbers of women were enrolled and the enroll-
ment of ESPRIT Vanguard patients in 1997–1999 – a
time when dual nucleoside therapy was the recom-
mended treatment in local ART guidelines – offer
some insights into this finding. In addition, the entry
requirement of a CD4+ T-cell count ≥300 cells/µL
may have affected the choice of ART at baseline,
especially if this count was higher than the recom-
mended level for ART commencement that was set
by treatment guidelines in the country of enroll-
ment. Overall, however, across the entire cohort,
approximately equal numbers of patients were on a
PI- or NNRTI-based combination at baseline, which
reflects adherence with the International AIDS Soci-
ety-USA (IAS) guidelines at the time that ESPRIT
was enrolling patients (2000–2003).
29 Longer dura-
tion of ART correlated with clinical and metabolic
manifestations of the HIV-lipodystrophy syndrome.
The lowest nadir CD4+ T cells, highest percentage of
patients with prior ADI, and longest duration of
antiretroviral use were seen in patients enrolled in
Europe and Australia. These findings suggest that
patients with advanced immunodeficiency as exem-
plified by low nadir CD4+ T cells (<100 cells/µL),
irrespective of whether they had developed an ADI,
were treated with ART in accordance with what
ART was available at that time and were “rescued”
clinically as a consequence. The magnitude of im-
mune restoration as illustrated by median difference
between the baseline and nadir CD4+ T-cell count
did not appear to be negatively impacted by lower
nadir CD4+ T-cell count. In Asia, the degree of im-
mune restoration was lowest despite these patients
having the highest nadir CD4+ T-cell counts; this
may have been a consequence of incomplete im-
mune restoration at the time of enrollment due to
shorter duration of ART or virological failure. The
low overall use of any kind of opportunistic infec-
tion (OI) prophylaxis reflects the high entry CD4+ T-
cell counts of the study participants and in patients
with a previously low CD4+ T-cell nadir might re-
flect the withdrawal of primary or secondary pro-
phylaxis in accordance with the IDSA guidelines.
30
Reported hepatitis B coinfection rates were
lower than expected, particularly in countries
where HBV is endemic. HCV but not HBV rates
mirrored reported rates of IVDU; this suggests
transmission through routes other than IVDU for
HBV, if the reporting of IVDU was accurate. The
relatively low rates of HBV (and to some extent
HCV) coinfection in the ESPRIT cohort may be
explained by patients not meeting the inclusion
criteria with respect to liver transaminases within
protocol-defined ranges (≤5 x the upper limit of
normal) or investigator anxiety regarding the po-
tential impact of rIL-2 on those with liver disease.
ESPRIT has enrolled patients from a large num-
ber of clinical sites on six continents. Moreover,
groups often underrepresented in HIV clinical tri-
als, such as women and patients of Asian and Afri-
can-American/African ethnicity, have been en-
rolled in relatively large numbers. As a
consequence, the acceptability of rIL-2 will be able
to be evaluated in these different populations. Fur-
thermore, the highly heterogenous patient sample
will aid the broad generalizability of results to all
patients with HIV infection.
ACKNOWLEDGMENTS
The National Centre in HIV Epidemiology and
Clinical Research is funded by the Australian Gov-
ernment Department of Health and Ageing and is
affiliated with the Faculty of Medicine, The Univer-
sity of New South Wales. ESPRIT is funded by the
National Institutes of Health under award 1U01
AI46957. Chiron Corporation provides recombi-
nant interleukin-2 (rIL-2) for this study, clinical
trial insurance in some countries, and assistance
with the procurement of HIV quantification assays
at some clinical sites. The US government has been
granted a patent for immunologic enhancement
using intermittent interleukin-2 that cites H.
Clifford Lane as an inventor.
REFERENCES
1. Finzi D, Hermankova M, Pierson T, et al. Identification of a
reservoir for HIV-1 in patients on highly active antiretroviral
therapy. Science. 1997;278:1295–1300.
2. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of
replication competent HIV despite prolonged suppression
of plasma viraemia. Science. 1997;278:1291–1295.
3. Bangsberg DR, Moss AR, Deeks SG. Paradoxes of adherence
and drug resistance to HIV antiretroviral therapy. J Antimicrob
Chemother. 2004;53(5):696–699. Epub 2004 Mar 24.ESPRIT • PETT ET AL. 81
4. John M, Nolan D, Mallal S. Antiretroviral therapy and the
lipodystrophy syndrome. Antiviral Ther. 2001;6:9–20.
5. Friis-Moller N, Sabin CA, Weber R, et al. Combination
antiretroviral therapy and the risk of myocardial infarction.
N Engl J Med. 2003;349(21):1993–2003.
6. Nelson M, Matthews G, Brook MG, et al. BHIVA guidelines
on HIV and chronic hepatitis: co-infection with HIV and
hepatitis C virus infection (2005). HIV Med. 2005;6 (Suppl
2):96–106.
7. Yeni PG, Hammer SM, Hirsch MS, et al. Antiretroviral treat-
ment for adult HIV infection. 2004 Recommendations of
the International AIDS Society-USA panel. JAMA.
2004;292(2):251–265.
8. Davey RT, Chaitt RT, Piscitelli SC, et al. Subcutaneous
administration of interleukin-2 in human immunodeficiency
virus type-1 infected persons. J Infect Dis. 1997;175:781–
789.
9. Carr A, Emery S, Lloyd A, et al. Outpatient continuous
intravenous interleukin-2 or subcutaneous, polyethylene
glycol modified interleukin-2 in human immunodeficiency
virus-infected patients: a randomized, controlled,
multicenter study. J Infect Dis. 1998;178:992–999.
10. Levy Y, Capitant C, Houhou S, et al. Comparison of subcu-
taneous and intravenous interleukin-2 in asymptomatic
HIV-1 infection: a randomised controlled trial. ANRS 048
study group. Lancet. 1999;353:1923–1929.
11. Davey RT, Chaitt D, Albert JM, et al. A randomized trial of
high- versus low-dose subcutaneous interleukin-2 outpa-
tient therapy for early human immunodeficiency virus type-
1 infection. J Infect Dis. 1999;179:849–858.
12. Miller KD, Spooner K, Herpin BR, et al. Immunotherapy of
HIV-infected patients with intermittent interleukin-2: effects
of cycle frequency and cycle duration on degree of CD4+
T-lymphocyte expansion. Clin Immunol. 2001;99(1):30–42.
13. Davey RT, Murphy RL, Graziano FM, et al. Immunologic
and virologic effects of subcutaneous interleukin-2 in com-
bination with antiretroviral therapy: a randomised con-
trolled trial. JAMA. 2000;284:183–189.
14. Abrams DI, Bebchuk JD, Denning ET, et al. Randomised,
open-label study of the impact of two doses of subcutane-
ous recombinant interleukin-2 on viral burden in patients
with HIV-1 infection and CD4+ cells counts  300/mm 3:
CPCRA 059. J AIDS. 2002;29:221–231.
15. Arduino RC, Nannini EC, Rodriguez-Barradas, et al. CD4
cell response to 3 doses of subcutaneous interleukin 2:
meta-analysis of 3 Vanguard studies. Clin Infect Dis.
2004;39(1):115–122. Epub 2004 Jun 14.
16. Natarajan V, Lempicki RA, Sereti I, et al. Increased periph-
eral expansion of naïve CD4+ T cells in vivo after IL-2
treatment of patients with HIV infection. PNAS.
2002;99(16):10712–10717.
17. Sereti I, Martinez-Wilson H, Metcalf JA, et al. Long-term
effects of intermittent interleukin-2 therapy in patients with
HIV infection: characterization of a novel subset of CD4+/
CD25+ T-cells. Blood. 2002;100(6):2159–2167.
18. Kovacs JA, Lempicki RA, Sidorov IA, et al. Induction of
prolonged survival of  CD4+ T-lymphocytes by intermittent
IL-2 therapy in HIV-infected patients. J Clin Invest.
2005;115:2139–2148.
19. Emery S, Capra WB, Cooper DA, et al. Pooled analysis of 3
randomized, controlled trials of interleukin-2 therapy in
adult human immunodeficiency virus type 1 disease. J
Infect Dis. 2000;182:428–434.
20. Emery S, Abrams DI, Cooper DA, et al. The evaluation of
subcutaneous Proleukin (interleukin-2) in a randomised in-
ternational trial: rational, design and methods of ESPRIT.
Control Clin Trials. 2002;23(2):198–220.
21. www.silcaat.org
22. Tavel JA, Fosdick L, et al. Close out of four phase II
vanguard trials and patient roll-over into a large interna-
tional phase III HIV clinical endpoint trial. Cont Clin Trials.
2001;22:42–48.
23. Centers for Disease Control and Prevention. 1993 revised
classification system for HIV infection and expanded sur-
veillance case definition for AIDS among adolescents and
adults. MMWR. 1992;41:1–20.
24. Neaton JD, Wentworth DN, Rhame F, et al. Methods of
studying interventions: considerations in choice of a clini-
cal endpoint for AIDS clinical trials. Stat Med.
1994;13:2107–2125.
25. Gandhi MN, Ameli P, Bacchetti GB, et al. Eligibility criteria
for HIV clinical trials and generalisability of results: the gap
between published reports and study protocols. AIDS. In
press.
26. www.fda.gov
27. Egger, M, May M, Chene G, et al. Prognosis of HIV-1
infected patients starting highly active antiretroviral
therapy: a collaborative analysis of prospective studies.
Lancet. 2002;360:119–129.
28. Mocroft A, Lederberger B, Katlama C, et al. Decline in the
AIDS and death rates in the EuroSIDA study: an observa-
tional study. Lancet. 2003;362:22–29.
29. Carpenter CC, Cooper DA, Fischl MA, et al. Antiretroviral
therapy in adults: updated recommendations of the Inter-
national AIDS Society-USA Panel. JAMA.
2000;283(3):381–390.
30. Masur H, Kaplan JE, Holmes KK, U.S. Public Health Ser-
vice, Infectious Diseases Society of America. Guidelines
for preventing opportunistic infections among HIV-infected
persons—2002. Recommendations of the U.S. Public
Health Service and the Infectious Diseases Society of
America. Ann Intern Med. 2002;137(5 Pt 2):435–478.82 HIV CLINICAL TRIALS • 7/2 • MAR-APR 2006
APPENDIX A
ESPRIT Study Group:  An International Steering
Committee that includes the Executive Committee
and representatives from National and Regional
Coordinating Centers oversee the trial. Co-chairs
of the ESPRIT study are Donald I. Abrams and
David A. Cooper. Representatives from each
national group and key committees are named
below. Past and current members of the
International Steering Committee are in bold
typeface.
Executive Committee: Donald I. Abrams, David
A. Cooper, Janet H. Darbyshire, William R.
Duncan, Sean Emery, H. Clifford Lane, Sandra
Lehrman, Jens D. Lundgren, James D. Neaton.
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Aguilar, Eleonora Betina Angel, Silvia Aquilia,
Waldo Belloso, Jorge Benetucci, Victor Bittar,
Pedro Cahn, Arnaldo Casiro, Jorge Contarelli,
Jorge Corral, Lucia Daciuk, Daniel David, Ines
Ferrari, Diego Fridman, Viviana Galache, Graciela
Guaragna, Silvina Ivalo, Hector Laplume, Maria B.
Lasala, Roberta Lattes, Jaime Lasovsky, Gustavo
Lopardo,  Marcelo Losso, Leonardo Lourtau,
Sergio Lupo, Aldo Maranzana, Cristina Marson,
Lucila Massera, Marisa del Lujan Sanchez, Carla
Somenzini, Mariel Tocci.
Australia National Trial Coordinating Center:
Sally Algar, Jonathan Anderson, David Austin,
David Baker, Kathy Blavius, Mark Bloch, Michael
Boyle, David Bradford, Leah Carrall, Andrew Carr,
John Chuah, Michael Curry, Clive D’Arcy-Evans,
Pauline Dobson, Nicholas Doong, Wendy
Ferguson,  Robert Finlayson,  Martyn French,
Julian Gold, Philip Habel, Jennifer Hoy, Jeff
Hudson, Robyn James, Sarangapany Jeganathan,
Jenny Leung, Kaye Lowe, Karen MacRae, Simon
Mallal, Marilyn McMurchie, Nicholas Medland,
Anne Mijch, Samantha Miller, Jo Murray, David
Orth, Julie Patching, Ruth Primrose, Dick Quan,
Michael Rawlinson, Hugo Ree, Robyn Richardson,
Gary Rogers, Janine Roney, Norman Roth, David
Shaw, Tuck Meng Soo, David Sowden, Alison
Street, Alan Street, Robyn Vale, Claudio Villella,
Allen Walker, Ashley Watson, Ngaire Wendt,
Helen Wood, David Youds.
Austria National Trial Coordinating Center:
Alexander Aichelburg, Armin Rieger, Norbert
Vetter.
Belgium National Trial Coordinating Center:
Nathan Clumeck, Stèphane De Wit, Kabamba
Kabeya, Elizabeth O’Doherty.
Brazil National Trial Coordinating Center:
Caritas Relva Basso, Cristiane de Sales Amorim,
David Salamão Lewi, Tamara Newman Lobato
Souza, Luiz Carlos Pereira, Mariliza da Silva.
Canada National Trial Coordinating Center:
Jonathan Angel, Pierrette-Rolande Bouchard, Fran
Clark, Jeff Cohen, Mimose Dambreville, Michele
Ellis, Stephan Fiset, Andrea Foster, Christopher
Fraser, Susan Gagnon, Janet Gilmour, Richard
Guenette, Heather Haldane, Nanci Hawley-Foss, Su-
san Hyndman, Lynn Johnston, Nathalie Jubinville,
Francoise Juneau, Lynn Kelleher, Lyne LaPointe,
Judy Latendre-Paquette, Adeline Lindemulder,
Laura Mashinter, Eric Lefebvre, Nancy McFarland,
Chantal Morisseau, Robert O’Neill, Alain Piche, Ed-
ward Ralph, Danielle Rouleau, Jean-Pierre Routy,ESPRIT • PETT ET AL. 83
Roger Sandre, Shelley Schmidt, Stephen Shafran,
Fiona Smaill, Dale Stromberg, Jean-Marc Trepanier,
Sylvie Trottier, Susanne Veal, Sharon Walmsley, Karl
Weiss, Kurt Williams, Mavis Young, Barbara
Zaleschuk, Don Zarowny.
Denmark National Trial Coordinating Center:
Bente Baadegaard, Finn Black, Kirsten Boedker,
Jan Gerstoft, Lene Jensen, Lars Mathiesen, Henrik
Nielsen,  Court Pedersen, Dorthe Petersen.
France National Trial Coordinating Center: Jean-
Pierre Aboulker, Adyb Baakili, Nafissa Bengrait,
Maryse Bensalem, Huguette Berthe, Martin Bloche,
Claude Bazin, Francois Boue, Elisabeth Bouvet,
Christiane Brancon, Catherine Capitant, Carole
Ceppi, Christine Cheneau, Anne Coutellier, Jean
Marie Chennebault, Fabienne Coquet, Pierre De
Truchis, Anne-Marie Delavalle, Veronique Frixon-
Marin, Jean-Albert Gastaut, Francois Delfraissy,
Muriel Eliaszeicz, Herve Gallais, Jean-Albert
Gataut, Jacques Gilquin, Gustavo Gonzalez-Canali,
Chrisiane Gaudebout, Cecile Goujard, Bruno
Hoen, Patricia Honore, Bernard Jarousse, Jean-
Marie Lang, Benedict Lefebvre, Yves Levy,
Jocelyne Loison, Aline Maignan, Jean-Luc
Meynard, Christophe Michon, Martin Mole,
Laurence Marsal, Sophie Matheron, Emmanuel
Mortier, Eric Oksenhendler, Sandrine Poirier,
Catherine Picard-Dahan, Isabelle Ravaux, Francois
Raffi, Gilles Raguin, Jacque Reynes, Willy
Rozenbaum, Dominique Salmon, Anne Simon,
Gabriella Spiridon, Jean-Paul Viard, Michele Vidal,
Laurence Weiss, David Zucman.
Germany National Trial Coordinating Center:
Frank Bergmann, Norbert Brockmeyer, Gerd
Faetkenheuer, Stefan Fenske, Daniela Gey, Frank-
Detlef Goebel, Martina Goetsch, Martin Hartmann,
Hartwig Klinker, Gisela Kremer, Kathleen
Mantzsch, Stefan Mauss, Juergen Rockstroh, Jes-
sica Rotty, Ellen Rund, Katrin Schneider, Dirk
Schuermann,  Schlomo Staszweski, Klaus
Tilmann, Martin Vogel.
Israel National Trial Coordinating Center: Zvi
Bentwich, Goldstain Drora, Eynat Kedem, Ruth
Lang, Itzic Levi, Shlomo Maayan, Eli Magen,
Merav Mamorsky, Anat Pilpul, Shimon Pollack,
Zev Sthoeger, Hadas Vered, Israel Yust.
Ireland National Trial Coordinating Center:
Fiona Lyons, Fiona Mulcahy, Annette Rochford.
Italy National Trial Coordinating Center:
Fernando Auiti, Gioacchino Angarano, Davide
Bertelli, Teresa Bini, Raffaele Bruno, Gian Pietro
Cadeo, Giampietro Carosi, Antonella D’Arminio
Monforte, Sergio Del Giacco, Massimo Di Pietro,
Roberto Esposito, Gaetano Filice, Gabriella
Gavazzeni, Giovanni Guaraldi, Francesco
Indiveri, Adriano Lazzarin, Francesco Mazzotta,
Lorenzo Minolli, Maria Montroni, Mauro Moroni,
Silvia Nozza, Guiseppe Pastor, Guido Poli, Enzo
Raise, Sergio Romagnani, Vega Rusconi, Paolo
Sacchi, Fredy Suter, Giuseppe Tambussi,
Umberto Tirelli.
Japan National Trial Coordinating Center: Helen
Fraser, Aikichi Iwamoto, Yoshida Kikuchi,
Masahiko Mori, Tetsuya Nakamura, Takashi
Odawara, Shinichi Oka, Takuma Shiasaka, Misao
Takano, Junichiro To, Chisato Ueta.
Morocco National Trial Coordinating Center:
Kamal El Filali, Hakima Himmich.
Netherlands National Trial Coordinating Center:
W. Blok, J. Borleffs, B. Bravenboer, W. Bronveld, F.
Claessen, Maurice Duurvoort, J. Ferwerda, P.
Frissen, Nicolette Hulshoff, Job Juttman, R.
Kauffmann, P. Koopmans, F. Kroon, Selwyn Lowe,
M. Leemhuis, P. Meenhorst, Peter Reiss, S.
Reinders-Folmer, C. Richter, Rick Santegoets,
Marijke Schoemaker, G. Schrey, Herman Sprenger,
Jacob Ten Veen, Judith Tessalaar, M. van der Ende,
H. van der Vall, Arne van Eeden, Remko van
Leeuwen, Joost Vermeulen, Reinier W. ten Kate,
Renee van Boxtel, Arne van Eden, Bernadette van
de Ven, Piet van der Meulen, C. ten Napei, R.
Vriesendrop.
Norway National Trial Coordinating Center:
Johann Bruun.
Poland National Trial Coordinating Center:
Elzbieta Bakowska, Marek Beniowski, Anna Bo-
ron-Kaczmarska, Jacek Gasiorowski, Andrzej
Gxadysz,  Andrzej Horban, Brygida Knysz,
Elzbieta Mularska, Magdelena Pynka, Aleksandra
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Portugal National Trial Coordinating Center:
Isabel Aldir, Francisco Antunes, Manuela
Doroana, Luís Duque, Kamal Mansinho, Inez
Pinto, Emilia Valadas, Jose Vera.
Singapore National Trial Coordinating Center:
Anushia Panchalingham, Poh Lian Lim, Nick
Paton, Bernard Peperstraete, Jorge Villacian.
Spain National Trial Coordinating Center:
Rosario Alcazar-Caballero, Julio Arrizabalaga,
Emilio Bouza, Concepcion Cepeda, Xabier de
Barron, Miguel Cervero Jimenez, Bonaventura
Clotet, Luis Cortes, Pere Domingo, Pompeyo
Fernandez, Eduardo Fernandez-Cruz, Montserrat
Fuster, Jose Gatell, Paloma Gijón, Ignacio Gil, Juan
Gonzales-Lahoz, Alicia Gonzalez, Manuel
Hernandez, Jose Iribarren, Miguel Jimenez,
Hernando Knobel, Agathe Leon, Juan Carlos
Lopez, Angeles Lozano, Paco Lopez, Jose Moreno,
Rosa Munoz, Belen Padilla, Angeles Parras, Antoni
Pastor, Jose Pedreira, Julio Pristo, Jose Pena, Victor
Roca, Rafael Rubio, Jose Sanchez de Rivera, Jesus
Sanz, Lara Tamargo, Rafael Torres.
Sweden National Trial Coordinating Center: Pehr
O. Pehrson, Eric Sandström.
Switzerland National Trial Coordinating Center:
Enos Bernasconi, Vanina Gurtner, Lorenzo Ma-
genta.
Thailand National Trial Coordinating Center:
Chureeratana Bowonwatnuwong, Mark Boyd,
Ploenchan Chetchotisakd, Thesinee Chuenyam,
Chris Duncombe, Pacharee Kantipong, Praphan
Phanuphak, Vithaya Pongsurachet, Kiat
Ruxrungtham, Samroeng Seekaew, Surapol
Suwanagool, Wichai Techasathit, Jaturaporn
Wankoon.
U.K. National Trial Coordinating Center:
Aderonke Adebiyi, Diana Aldam, Ian Alexander,
Brian Angus, Tristan Barber, Sue Bonnington,
Chris Care, Anne Carroll, David Cornforth, Oscar
Donaldson, Laurance Druiff, Philippa Easterbrook,
Beverley Edwards, Chris Ellis, Ikbale Erradey,
Kamal El Filali, Martin Fisher, Ray Fox, Brian
Gazzard, Allan Harrison, Sandra Herman, Lisa
Heald, Christopher Higgs, Hakima Himmich,
Isabelle Jendrulek, Margaret Johnson, Lucy Judges,
Fatimah Karim, George Kinghorn, Julie Laurenti,
Christine Lee, Clifford Leen, Ken Legg, Fiona
Lyons, Raymond Maw, Alisdair MacConachie,
Sinead McKernan, Lorna McLean, Andrew
McMillan, Sifiso Mguni, Sheila Morris, Fiona
Mulchay, Dee Mullan, Scott Mullaney, Maurice
Murphy, Andrew Nunn, Edmund Ong, Maxine
Owen, Adrian Palfreeman, Nicky Perry, Barry Pe-
ters, Anton Pozniak, Annette Rochford, Agnes
Ronan, Cecilia Skinner, Carol Stroud, Martin
Takawira, Norbert Tamm, Rachel Thomas, Thynn
Thynn Yee, An Vanthuyne, Mark Wansborough-
Jones, Jonathan Weber, David White, Ed Wilkins,
Martin Wiselka, Ian Williams, Mike Waugh, Joyce
Wotherspoon, Mike Youle.
U.S. Chicago National Trial Coordinating Center:
Margaret Doyle, Edward Goodwin, Roberta
Luskin-Hawk, James Sullivan, Rita Verheggen.
U.S. CPCRA National Trial Coordinating Center:
Donald Abrams, John Baxter, Carroll Child, David
Cohn, Pam Cooper, Wafaa El-Sadr, Martha
Farrough, Evelyn Fisher, Luis Fuentes, Edward
Goodwin, Fred Gordin, Carol Graeber, Mary Ellen
Kelly, Jay Kostman, Ann Labriola, Kelly Lattanzi,
Rodger MacArthur, Linda Makohon, Norman P.
Markowitz, Diane Mastro-Polak, Vinnie Mitchell,
David Mushatt, George Perez, Corey Rosmarin,
Jack R. Rouff, Jennifer Saldanha, James Sampson,
Robert Sawyer, Barbara Standridge, James
Sullivan, Bentley Sweeton, Ellen Tedaldi, Melanie
Thompson, Patricia Valencia, Gwen Verlinghieri,
Janice Walker, Vicky Watson.
U.S. Department of Defense National Trial Coor-
dinating Center: Adam Armstrong, Susan Banks,
David Blazes, Anthony Barile, Linda Coelho,
Marilyn Dennis, Hannah Flaks, Joyce Gilcrest,
Kathleen Gittens, Sheila Hooper, M. J. Humphries,
Katherine Spooner, Cindy L. Tamminga, Jean Vita,
Scott A. Wegner, Glenn Wortmann.
U.S. Department of Veterans Affairs National
Trial Coordinating Center: Nicole Bisby, William
Blake, Sheldon Brown, Phillippe Chilliade, Teresa
Cole, Katherine Elliot, Christiane Geisler, Matthew
Goetz, Elizabeth Gomez-Perez, Fred Gordin, Jami
Helman, Nancy Klimas, Ann Labriola, Ronald
Nahass, Dirk LeFlore, Barbara Marston, Maria
Obregon, Jennifer Petrolati, David L. Pitrak, RobertESPRIT • PETT ET AL. 85
Roland, Carol Rosa, Barbara Rossman, Susan
Schlueter Wirtz, Suzanne Schuck, Tiffany
Scretchings, Gary Simon, Mack Smith, Barbara
Standridge, Kimberley Summers, Mary Jo Werhane.
U.S. Houston National Trial Coordinating Cen-
ter: Roberto Arduino, Brian Bell, Katherine
Breaux, Hilda Cuervo, Carl Hale, Stanley Lewis,
Fransisco Mora, Martine M. Diez, Pablo Okhuysen,
Maria Rodriguez-Barradas, Shannon R. Schrader.
U.S. Miami National Trial Coordinating Center:
Lynn Healy, Chris Kaszubski, Michael Kolber,
Tom Tanner.
U.S. CORNET National Trial Coordinating Cen-
ter: Joann Armstrong, Jennifer Dahlke, Leonard
Johnson, Patricia Kaminski, Frank Rhame, Cheryl
Shoden, Zelalem Temesgen, Marcy Urbanich,
Sharon Valenti, Marcus Zervos.
U.S. NIAID National Trial Coordinating Center:
Rick Davey, Bill Barrick, Doreen Chaitt, Barbara
Hahn, Cliff Lane, Dennis Martell, Laura McNay,
Julia Metcalf, April Powers, Jorge A. Tavel.
U.S. Portland National Coordinating Center:
Karen Loveless, Norma Martinez, Sue Peterson,
James Sampson, Suzanne Sweek.
U.S. San Fransisco National Trial Coordinating
Center: Donald Abrams, Helmut Albrecht, Nicole
Antoine, Mary Ellen Kelly, Paula Pell.
Endpoint Review Committee: Waldo Belloso, Jose
Maria Gatell, Jenny Hoy, Alan Lifson, Court
Pederson, Frank Rhame, Wafaa El-Sadr.
Copenhagen Regional Coordinating Center:
Liselotte Borup, Ulrik Bak Dragsted, Anne Fau
Greve, Karoline Jensen, Jens Lundgren, David
Mollerup, Mary Pearson, Andrew Phillips.
London Regional Coordinating Center: Jamila
Aboulhab, Brian Angus, Abdel Babiker, Brooke
Cordwell, Janet Darbyshire, Douglas Newberry,
Lisa Hack, Malcolm Hooker, Yolanda Moraes,
Fionna van Hooff.
Minneapolis Regional Coordinating Center:
Eileen T. Denning, Leslie H. Klemme.
Sydney Regional Coordinating Center: Cate
Carey, Fonnie Chan, David Cooper, David
Courtney-Rodgers, Fraser Drummond, Sean Em-
ery, Simone Jacoby, Matthew Law, Morgan
Stewart, Sarah Pett.
Minnesota Coordinating Center: Zarina Alloo,
Judy Bebchuk, Patty Bollenbeck, Alain G.
DuChene, Lisa Fosdick, Merrie Harrison, Eric
Krum, Gregg Larson, Alan Lifson, Sue Meger,
James Neaton, Ray Nelson, Siu-Fun L. Quan, Terri
Schultz, Susan Telke, Lisa Thackeray, Greg Th-
ompson, Nicole Wyman.
National Institute of Allergy and Infectious Dis-
ease, Division of AIDS: William Duncan, Elaine
Ferguson, Lawrence Fox, Nikki Gettinger, Janet
Herrera,  Sandra Lehrman, Mary Anne Luzar,
Mieko Maeshiro, Ana Martinez, Karen Oseekey.
Chiron Corporation: Greg Baigent, William Capra,
Anne-Marie Duliege, Linda Fitzgerald, Marthin
Kwakkelstein, Jean Maral, Mary O’Hara, David
Sahner, Claire Weber.
International Drug Distribution (CTS Inc.,
Durham, North Carolina):
Christine Adam-Perchec, Nigel Barron, Mary
Louise Bell, Sandra Dolan, Julie Eckstrand, Steven
Hicks, George McAuley.
SAIC Frederick, Inc. (specimen repository):
Sharon Beck, Shawn Brown, Adam Rupert.